Update on T-cell lymphoma.
Vose
J M
JM
Internal Medicine, UNMC, Omaha, NE, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005843:Geography; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D016399:Lymphoma, T-Cell / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy; D016019:Survival Analysis; D014944:World Health Organization; D000093542:Gemcitabine
D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D003841:Deoxycytidine; D000093542:Gemcitabine